



Final Appraisal Recommendation

Advice No: 2118 – November 2018

Tiotropium (Spiriva® Respimat®) 2.5 microgram, inhalation solution

Limited submission by Boehringer Ingelheim Ltd

Recommendation of AWMSG

Tiotropium (Spiriva® Respimat®) is recommended as an option for use within NHS Wales as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.

Additional note(s):

- This advice incorporates and replaces the existing AWMSG recommendation for tiotropium (Spiriva® Respimat®) as an option for use within NHS Wales as an add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥ 800 micrograms budesonide daily or equivalent) and long acting beta2-agonists and who experienced one or more severe exacerbations in the previous year. (AWTTC reference number 3436, originally published October 2017).
- The whole licenced indication wording was revised at the time of the paediatric licence extension and is now the same for adults and children; the specification of inhaled corticosteroid dose and the number of concomitant controller medicines has been moved to Section 4.2 of the Summary of Product Characteristics.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1882), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 2118:
Tiotropium (Spiriva® Respimat®) 2.5 microgram, inhalation solution. November 2018

